Celltrion, Inc. (068270.KS)
KRW 159200.0
(0.06%)
KRW 159200.0
(0.06%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2176.43 Billion KRW | -4.71% |
| 2022 | 2283.96 Billion KRW | 19.48% |
| 2021 | 1911.6 Billion KRW | 3.38% |
| 2020 | 1849.11 Billion KRW | 63.86% |
| 2019 | 1128.45 Billion KRW | 14.91% |
| 2018 | 982.07 Billion KRW | 3.48% |
| 2017 | 949.07 Billion KRW | 41.53% |
| 2016 | 670.58 Billion KRW | 11.13% |
| 2015 | 603.41 Billion KRW | 28.1% |
| 2014 | 471.04 Billion KRW | 108.24% |
| 2013 | 226.2 Billion KRW | -35.41% |
| 2012 | 350.19 Billion KRW | 25.5% |
| 2011 | 279.04 Billion KRW | 54.21% |
| 2010 | 180.94 Billion KRW | 24.32% |
| 2009 | 145.55 Billion KRW | 73.92% |
| 2008 | 83.68 Billion KRW | 39.29% |
| 2007 | 60.08 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 874.74 Billion KRW | 18.69% |
| 2024 Q1 | 736.98 Billion KRW | 92.63% |
| 2023 FY | 2176.43 Billion KRW | -4.71% |
| 2023 Q4 | 382.59 Billion KRW | -43.09% |
| 2023 Q1 | 597.56 Billion KRW | 17.02% |
| 2023 Q3 | 672.29 Billion KRW | 28.31% |
| 2023 Q2 | 523.97 Billion KRW | -12.31% |
| 2022 Q4 | 510.63 Billion KRW | -20.91% |
| 2022 Q3 | 645.63 Billion KRW | 8.32% |
| 2022 Q2 | 596.06 Billion KRW | 8.26% |
| 2022 Q1 | 550.59 Billion KRW | -11.47% |
| 2022 FY | 2283.96 Billion KRW | 19.48% |
| 2021 Q3 | 400.95 Billion KRW | -7.14% |
| 2021 Q1 | 456.96 Billion KRW | -8.37% |
| 2021 Q2 | 431.76 Billion KRW | -5.51% |
| 2021 FY | 1911.6 Billion KRW | 3.38% |
| 2021 Q4 | 621.9 Billion KRW | 55.11% |
| 2020 Q4 | 498.69 Billion KRW | -9.12% |
| 2020 FY | 1849.11 Billion KRW | 63.86% |
| 2020 Q1 | 372.84 Billion KRW | -2.58% |
| 2020 Q3 | 548.77 Billion KRW | 27.98% |
| 2020 Q2 | 428.79 Billion KRW | 15.01% |
| 2019 Q1 | 221.7 Billion KRW | -8.59% |
| 2019 FY | 1128.45 Billion KRW | 14.91% |
| 2019 Q3 | 289.05 Billion KRW | 23.02% |
| 2019 Q4 | 382.72 Billion KRW | 32.41% |
| 2019 Q2 | 234.97 Billion KRW | 5.99% |
| 2018 Q3 | 231.1 Billion KRW | -12.27% |
| 2018 Q4 | 242.55 Billion KRW | 4.95% |
| 2018 FY | 982.07 Billion KRW | 3.48% |
| 2018 Q1 | 244.98 Billion KRW | -10.68% |
| 2018 Q2 | 263.43 Billion KRW | 7.53% |
| 2017 Q2 | 246.14 Billion KRW | 25.22% |
| 2017 FY | 949.07 Billion KRW | 41.53% |
| 2017 Q4 | 274.26 Billion KRW | 18.17% |
| 2017 Q3 | 232.08 Billion KRW | -5.71% |
| 2017 Q1 | 196.57 Billion KRW | -5.86% |
| 2016 Q4 | 208.81 Billion KRW | 24.1% |
| 2016 Q3 | 168.27 Billion KRW | -9.06% |
| 2016 Q1 | 108.45 Billion KRW | -35.55% |
| 2016 FY | 670.58 Billion KRW | 11.13% |
| 2016 Q2 | 185.03 Billion KRW | 70.6% |
| 2015 Q1 | 97.62 Billion KRW | -2.23% |
| 2015 Q3 | 169.45 Billion KRW | 0.83% |
| 2015 Q4 | 168.28 Billion KRW | -0.69% |
| 2015 Q2 | 168.05 Billion KRW | 72.14% |
| 2015 FY | 603.41 Billion KRW | 28.1% |
| 2014 Q2 | 179.16 Billion KRW | 106.23% |
| 2014 FY | 471.04 Billion KRW | 108.24% |
| 2014 Q4 | 99.85 Billion KRW | -5.02% |
| 2014 Q3 | 105.14 Billion KRW | -41.32% |
| 2014 Q1 | 86.87 Billion KRW | 3059.93% |
| 2013 Q3 | 80.85 Billion KRW | 30.81% |
| 2013 FY | 226.2 Billion KRW | -35.41% |
| 2013 Q4 | 2.74 Billion KRW | -96.6% |
| 2013 Q1 | 80.79 Billion KRW | -25.71% |
| 2013 Q2 | 61.81 Billion KRW | -23.5% |
| 2012 FY | 350.19 Billion KRW | 25.5% |
| 2012 Q1 | 79.84 Billion KRW | 0.0% |
| 2012 Q3 | 80.96 Billion KRW | 0.75% |
| 2012 Q4 | 108.75 Billion KRW | 34.32% |
| 2012 Q2 | 80.35 Billion KRW | 0.65% |
| 2011 Q3 | 72.7 Billion KRW | 6.02% |
| 2011 Q2 | 68.57 Billion KRW | 14.22% |
| 2011 Q1 | 60.03 Billion KRW | 16.19% |
| 2011 FY | 279.04 Billion KRW | 54.21% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 Q2 | 42.91 Billion KRW | 23.01% |
| 2010 Q1 | 34.88 Billion KRW | 36.69% |
| 2010 Q3 | 51.48 Billion KRW | 19.98% |
| 2010 Q4 | 51.66 Billion KRW | 0.36% |
| 2010 FY | 180.94 Billion KRW | 24.32% |
| 2009 Q4 | 25.52 Billion KRW | -29.92% |
| 2009 FY | 145.55 Billion KRW | 73.92% |
| 2009 Q3 | 36.41 Billion KRW | -15.02% |
| 2009 Q2 | 42.85 Billion KRW | 5.16% |
| 2009 Q1 | 40.75 Billion KRW | 112.95% |
| 2008 Q1 | 12 Billion KRW | 0.0% |
| 2008 Q3 | 39.21 Billion KRW | 214.48% |
| 2008 Q4 | 19.13 Billion KRW | -51.2% |
| 2008 FY | 83.68 Billion KRW | 39.29% |
| 2008 Q2 | 12.47 Billion KRW | 3.85% |
| 2007 Q4 | - KRW | -100.0% |
| 2007 Q2 | 10.69 Billion KRW | -7.82% |
| 2007 Q1 | 11.6 Billion KRW | 0.0% |
| 2007 FY | 60.08 Billion KRW | 0.0% |
| 2007 Q3 | 13.04 Billion KRW | 21.93% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ORIENT BIO Inc. | 28 Billion KRW | -7671.547% |
| Green Cross Holdings Corporation | 2057.93 Billion KRW | -5.758% |
| Green Cross Holdings Corporation | 1626.64 Billion KRW | -33.799% |
| Pharmicell Co., Ltd. | 56.22 Billion KRW | -3770.768% |
| Green Cross Corporation | 1626.64 Billion KRW | -33.799% |
| GeneOne Life Science, Inc. | 40.2 Billion KRW | -5313.617% |
| Samsung Biologics Co.,Ltd. | 3694.58 Billion KRW | 41.091% |
| SK bioscience Co.,Ltd. | 369.5 Billion KRW | -489.012% |
| SK Biopharmaceuticals Co., Ltd. | 354.89 Billion KRW | -513.267% |
| Prestige BioPharma Limited | 689.07 Million KRW | -315748.279% |